Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Keytruda extends survival in first-line head and neck cancer trial

pharmatimesJuly 26, 2018

Tag: KEYNOTE-048 , pembrolizumab , PD-L1

PharmaSources Customer Service